Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clonidine/oxybutynin - Orient Pharma

Drug Profile

Clonidine/oxybutynin - Orient Pharma

Alternative Names: DL 06001; OP-014; SMT D001

Latest Information Update: 25 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DanioLabs
  • Developer Orient Pharma
  • Class Alkynes; Analgesics; Antiglaucomas; Antimigraines; Antispasmodics; Behavioural disorder therapies; Carbocyclic acids; Centrally-acting antihypertensives; Chlorobenzenes; Cyclohexanes; Diethylamines; Esters; Imidazolines; Mandelic acids; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Imidazoline receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Sialorrhoea

Most Recent Events

  • 25 Jan 2019 Clonidine/oxybutynin is not yet available for Sialorrhoea in Australia and Singapore (PO)
  • 25 Jan 2019 No recent reports of development identified after preregistration for Sialorrhoea in USA, European Union, Canada, China, China, Japan, Philippines, Hong Kong, Malaysia, India, New Zealand, South Korea (PO)
  • 04 Feb 2016 Preregistration for Sialorrhoea in European Union (PO) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top